SOME OF OUR PARTNERS

Why Work With Us?

Our services are unique and bespoke, we work with you in agile, collaborative teams to solve real development challenges.
Oncology & Modelling Specialists

Our specialisation in oncology means we offer you deep oncology modelling expertise, helping you save time and money.

Unique Virtual Tumour™ Technology

Virtual Tumour™ is our latest proprietary model-aided simulation to help improve the success rate of drug development.

Industry & Academic Experience

Based in Oxford, our team of experts have accumulated over 120 years of experience across pre-clinical and clinical pharmacology.

Agile Collaborations

Our skilled teams are agile, collaborative and efficient. We work with you to solve real development challenges.

Our Services

We support all phases of R&D. Our core capabilities include:
PK/PD Modelling

Construct Pharmacokinetic (PK) & Pharmacodynamic (PD) models to evaluate dose response.

Virtual Tumour™ Technology

Virtual Tumour will help you simulate tumours under the effects of any combination of anti-cancer agents.

Quantitative Systems Pharmacology

Create mechanistic models to provide you with valuable insights.

Personalised Oncology

Discover Physiomics’ innovative tool for the personalised treatment of cancer.

Experience the Power of Virtual Tumour™ Technology

Utilise our advanced proprietary technology to help accelerate drug development.

Virtual Tumour™ has been developed and refined based on years of experience in simulating a huge variety of cancer types, targets and drugs.

Predicts behavior over full time course

Combines the effects of drugs with different MOAs

Allows complex dosing and scheduling options

New data can be quickly incorporated

Helps explain behaviour of combination regimes

Model revisions and simulations can be delivered in real-time

Learn more CONTACT US
Personalised Cancer Treatment

Prostate cancer affects 47,000 men per year in the UK and metastatic disease has less than a 30% 5-yr survival rate.

Physiomics is developing an innovative new Precision Dosing tool for the personalisation of docetaxel treatment of late stage castrate-resistant prostate cancer.  If it were to be approved by regulatory authorities, the tool would potentially be able to:

Substantially reduce the occurrence of both under-dosing and over-dosing, leading to improved patient outcomes

Reduce costs associated with toxicity-related interventions and drug waste

Help postpone the need for subsequent expensive lines of treatment.

Learn more CONTACT US
Case Study

Physiomics is increasingly working with companies at the stage of pre-clinical to clinical translation and has been able to work closely with its clients to provide supporting materials for use with third parties such as regulatory agencies.  Here we provide an example from a project where the client was already in Phase 1 for one indication and wanted supporting evidence for dosing in a new indication.

FIND OUT MORE

A Track Record of Success

We have a strong track record of success working with big pharma, research and academia
Reduction in Number of Studies

*Combination case studies have shown that we can save between 8 and 18 groups of mice.

Reduction in Cost and Time

*Optimal combination schedules could be obtained in 3 months instead of 6 or 9 months.

Increased Success Rate

*Predicted improved regimen which was better than expert opinion.

* [Achievements are derived from specific client projects and will vary subject to the project].

70

Projects Completed

90

Targets & Drugs Modelled

120

Years of Combined Experience

122

Publications

Interested in Finding Out More?

Send us your query and we’ll put you in touch with the relevant expert in our team.

 


Physiomics is committed to protecting your privacy. Please acknowledge that you have read our Legal & Privacy Policy before proceeding.

Physiomics Plc

The Magdalen Centre
Oxford Science Park
1 Robert Robinson Avenue
Oxford OX4 4GA

Telephone

+44 (0) 1865 784980

})(jQuery)